The human myeloid cell line HL60 secretes urokinase-type plasminogen activator (uPA) and expresses its receptor. When stimulated with phorbol myristate acetate (PMA), both secretion of uPA and the expression of its receptor are up-regulated, and these cells differentiate to an adherent phenotype. This adhesive response is markedly reduced in the presence of uPA antibodies. The PMA response is restored by the addition of native uPA, an amino-terminal fragment of uPA (residues 1-143) devoid of proteolytic activity, or a synthetic peptide (residues 12-32) from the uPA growth factor domain known to mediate receptor binding. In contrast, the addition of catalytically active low molecular weight uPA, which is missing the growth factor domain, or a peptide from the catalytic domain (residues 247-266) is ineffective. The influence ofuPA antibodies on a second marker of macrophage differentiation, cysteine proteinase activity, was also examined. Cysteine proteinase activity of HL60 cells is increased in PMA-treated cells after 24 h but it fails to increase in the presence of anti-uPA. This increase in cathepsin B-like activity is also restored by exogenous uPA. These experiments indicate that an autocrine interaction of the growth factor domain of uPA with its receptor mediates an essential step in PMA-mediated myeloid cell differentiation. (J. Clin.
Introduction
Many mammalian cells synthesize and release urokinase-type plasminogen activator (uPA) (1) .' Expression of this enzyme has been implicated in a wide variety of biological processes including cellular migration, connective tissue matrix turnover, trophoblastic implantation, and tumor transformation (2) (3) (4) (5) . Many if not all of the cells which secrete uPA, including myeloid cell lines, monocytes, and macrophages, also express a high-affinity uPA receptor (1, (6) (7) (8) (9) (10) . The amino-terminal region of the uPA molecule, termed the growth factor domain (residues 1-32), mediates binding of uPA to this receptor (1 1). Receptor-bound uPA on mononuclear phagocytes has a relatively long half-life (hours) and may be protected from inhibition by soluble plasminogen activator inhibitors, facilitating cellular migration and cell-mediated connective tissue turnover (12) (13) (14) (15) . Thus, one established role for cellular expression of uPA and its receptor is to focus plasminogen activator activity to the cell surface.
When stimulated with PMA, the anchorage-independent myeloid cell lines, THP-1, U937 and HL60, differentiate to an adherent phenotype that have many characteristics of macrophages (16) (17) (18) (19) . Among the known changes which follow PMA stimulation are increased secretion of uPA as well as increased expression of uPA receptors (8, 9, (20) (21) (22) . We now show that binding of the growth factor domain of uPA to its receptor plays an essential role in PMA-mediated myeloid cell adhesion and maturation. These data extend the functions ascribed to the uPA receptor to one that includes a role in signal transduction. The manuscript details work done with the HL60 cell line. However, the observations are similar for the PMA-responsive human leukemic THP-1 and U937 cells, indicating the generality of this phenomenon.
Methods
Reagents. RPMI 1640 was from Gibco Laboratories, Grand Island, NY; bovine fetal serum from Hyclone, Logan, UT; and tissue cultureware from Falcon Labware, Lincoln Park, NJ. Cell lines HL60, U937, and THP-1 cells were obtained from American Type Culture Collection, Rockville, MD. [3H]thymidine (2 Ci/mmol) was from New England Nuclear, Boston, MA. Two-chain high molecular weight urokinase was a gift of the American Red Cross, and 2 99% pure recombinant two-chain high molecular weight urokinase (103,900 IU/mg) from Chinese hamster ovary cells was a gift of Dr. Robert Broeze, Collaborative Research, Bedford, MA. 33-kD low molecular mass uPA (no detectable 54-kD uPA by zymography [23] ), murine monoclonal anti-uPA (No. 377) and (No. 394), and protein-A affinity-purified rabbit anti-uPA (No. 389) were obtained from American Diagnostica, Greenwich, CT. Polyclonal rabbit anti-uPA (No. 6200) was purchased from Alpha Therapeutics, Los Angeles, CA. The amino-terminal fragment of uPA, residues 1-143, was a gift of Dr. Jack Henkin, Abbott Laboratories, Abbott Park, IL (24 Cell culture. HL60 and U937 cells were cultured in RPM1 1640 supplemented with penicillin (100 U/ml), streptomycin (100 ,ug/ml), and 10% bovine fetal serum. For THP-1 cell culture medium, 48 ,uM 2-mercaptoethanol was added to the mixture described above. Human alveolar macrophages were cultured in Dulbecco's modified Eagle's medium supplemented with 20 mM Hepes, penicillin (100 U/ml), streptomycin (100 ,ug/ml), and 10% bovine fetal serum. All incubations were at 37°C, 5% C02/95% air and cells were plated at 1 X 106/ml. The cell lines were differentiated along the macrophage pathway with 16 nM PMA (16 (8, 9) . Iodinated recombinant uPA was incubated in 3 X 10-12 to 9 x 10-9 M range with and without 100-fold excess cold uPA for 2 h on ice. Bound radioactivity was separated by centrifugation through an oil cushion of 1:1 mixture of silicone oil and dioctylphthalate. Microfuge tips were cut and counted in a gamma counter. Initial studies confirmed previously reported observations of others that HL60 cells have specific saturable receptors for uPA in the subnanomolar range and that the receptor number increases five-to eightfold after overnight stimulation with PMA (9) .
Assay ofprourokinase antigen by ELISA. HL60 cells were maintained in serum free media containing 0.1% BSA supplemented with insulin, transferrin and selenium as described (21) . Supernatants from control or overnight PMA stimulated cells were concentrated using filters with a I0-kD cutoff from Amicon Corp., Danvers, MA. The sandwich ELISA consisted of a uPA monoclonal (No. 394) for antigen capture, polyclonal rabbit anti-uPA (No. 6200) as the second layer, and alkaline-phosphatase labeled goat anti-rabbit IgG for detection (29) . This assay has no cross reactivity to tissue plasminogen activator. Fibrin zymography (23) verified that the supernatants from these cells contained a plasminogen activator that comigrated as a single clear 54-kD band identical to purified uPA. We found that the amount of prourokinase antigen in the supernatants of PMA stimulated cells increases by about 15-fold as compared to control unstimulated cells, confirming work done by other investigators with the HL60 and U937 cell lines (21, 22) .
Flow cytometry. Control unstimulated, or PMA-stimulated cells were cultured overnight with anti-uPA (No. 6200), 30 jil/ml. PMA stimulated and anti-uPA treated nonadherent cells, 90% oftotal, were aspirated and treated with pH 3 buffer to remove any cell associated uPA (10). They were then exposed sequentially to uPA (2 nM), monoclonal anti-uPA (No. 377) (20 jg/ml), and fluoresceinated Fab2 goat anti-mouse. Hybridoma supernatants of clone TS 1/ 18 were used to assess CD 18 expression (25). Nonspecific fluorescence was defined as that measured on cells exposed to a mixture of murine IgG 1, IgG2a, and IgG2b (each 10 jg/ml) followed by fluoresceinated Fab2. Analysis was performed using an Ortho 2151 cytofluorograph.
Cysteineproteinase assay. Z-Phe-Arg-NMec was used as a substrate for cathepsin B-and L-like cellular cysteine proteinases employing an assay based on that described by Barrett (30) (31) (32) . Adherent and nonadherent cells were combined and centrifuged to separate them from supernatant fluid before lysis in a buffer composed of 20 mM sodium acetate, 1% Triton X-100, 3 mM EDTA at pH 5.5, and subjected to a freeze-thaw cycle three times. The fluorometric assay was performed by incubating 10-or 20-;il aliquots of lysates at 37°C in a total of one ml incubation buffer containing 20 mM acetate, 10 AM Z-Phe-Arg-NMec, 3 mM cysteine at pH 5.5 for 30 min. Incubation in the presence ofthe cysteine proteinase inhibitor L-3-carboxy-trans-2,3-epoxypropylleucylamido [4-guanidino] butane (E-64) was used to establish specificity of the assay (31) . Each (Fig. 1) . A similar effect of anti-uPA was observed on the PMA response of HL60 cells maintained in serum-free medium as well as with U937 and THP-1 cells (not shown). Nonimmune rabbit IgG and neutralizing anti-tissue factor antibody did not attenuate cellular adherence (26). The addition of control nonimmune IgG consistently resulted in more cells adhering than in PMA only wells (Fig. 1) . This observation was not explored further.
The anti-uPA effect illustrated in Fig. 1 24 -h PMA stimulated HL60 cells by . 85%. The viability of PMA-stimulated, antibody-treated, nonadherent cells was slightly reduced. These nonadherent cells were 15±5% (n = 6) trypan blue positive whereas control cells in culture were < 5% positive. However, the addition of exogenous uPA (100 nM) to these antibody-treated cells resulted in an increase in the number of adherent cells to values comparable to PMA only treated cells. This reversibility suggested that the reduction in adhesion was not due to toxicity and but rather involved a specific interaction of uPA with uPA antibodies.
Determination of the uPA domain(s) necessary for adhesion. As shown in Fig. 2 , uPA is a multidomain protein within the seine proteinase family. At the amino terminus is a growth factor domain followed by a connecting peptide, a kringle structure, and carboxy-terminal catalytic domain (1) . We tested various fragments of uPA for their ability to reverse the effect of anti-uPA shown in Fig. 1 . Previous work has established that a catalytically inactive amino-terminal fragment of uPA (ATF), residues 1-135, as well as synthetic peptides from the growth factor domain (residues 1-32) compete effectively with uPA for binding to the uPA receptor (1 1, 20) . A peptide comprising residues 12-32 (21 amino acids) from the growth factor domain (GFD-peptide) known to be effective in this competition was synthesized. As a control for the GFD-peptide, a peptide comprising residues 247-266 (20 amino acids) from the catalytic domain (CD-peptide) was also made. The seine proteinase inhibitor, DFP, irreversibly inactivates uPA (DFP-uPA), and DFP-uPA interacts with uPA receptor as avidly as the active enzyme (34) . Catalytically active 33-kD low Figure 2 . Schematic representation of the urokinase molecule and its fragments used in the experiments. The ATF used here consisted of residues (eight residues longer than the ATF originally described by Stoppelli et al. [20] ) and does not have the catalytic domain. LMW-uPA is the 33-kD form of the molecule comprising the catalytic domain and has no receptor binding activity. GFDpeptide is residues 12-32 from the growth factor domain, and CDpeptide is residues 247-266 from the catalytic domain. Diagram modified from Francis and Marder [54] . molecular weight form of uPA (LMW-uPA), a proteolytically cleaved product of the native molecule devoid of the aminoterminal fragment, does not bind to the uPA receptor (34) . All of these fragments and forms of uPA were tested for their ability to overcome the effect of anti-uPA on PMA-stimulated cells. Concentration (nM) Figure 3 . Inhibition of adhesion by anti-uPA antibodies is reversible. Experiments were performed as described in Fig. 1 with adherence measured as counts per minute [3H]thymidine. The various forms of uPA were added at the time of PMA pulse to test for their ability to overcome the effect of anti-uPA. The uPA fragments tested are described in Fig. 2 Fig. 4 . PMA stimulated cells are adherent and spread (Fig. 4 A) . In the presence ofanti-uPA very few cells adhere (Fig. 4 B) , but with the addition ofATF, 25 nM, the cells are again adherent and spread (Fig. 4 C) . The presence of more cells in Fig. 4 C is related to the amount of ATF used as illustrated in Fig. 3 . Higher concentrations of ATF result in almost two times more cells adhering than in PMA only control wells. These findings indicate that uPA fragments which include the growth factor domain, regardless of the catalytic domain, will promote the PMA-induced adherent phenotype.
Effect ofthe GFD peptide on PMA response. Data in Fig. S show that for PMA stimulated cells in the presence of antiuPA, portions of the uPA molecule possessing the GFD increase the number of adherent cells above control values. Therefore, the effect of the GFD-peptide itself on the PMA response was tested in the absence of uPA antibodies. The addition of the GFD-peptide at the time of PMA stimulation resulted in a dose-dependent increase in the number of adhering cells (Fig. 5) . When visualized using phase-contrast microscopy, the PMA and GFD-peptide stimulated cells appeared more well spread and dense compared with PMA only treated counterparts. This observation was additional support for a role ofthe growth factor domain in augmenting PMA-triggered maturation. In contrast, the control CD-peptide from the catalytic domain did not alter the number of adhering cells.
Effect ofexogenous urokinase on HL60 proliferation. It has been reported that for the CCL 20.2 human epidermal cell line that uPA can serve as an autocrine mitogen and stimulates thymidine incorporation (42 (7, 27 ). An overnight adherence assay similar to that I described in Fig. 1 , but without PMA was used. There was no difference in adherence between anti-uPA-treated or untreated macrophages (Table I) . Moreover, uPA antibodies added to HL60 cells 72 h after PMA stimulation did not result in appre- synthetic substrate Z-phe-arg-NMec at pH 5.5 (30) (31) (32) . Fig. 6 illustrates that the lysates of PMA-treated cells have an almost twofold increase in cathepsin B-like activity when compared with untreated HL60 cells (P < 0.05, n = 4). The class specific cysteine proteinase inhibitor E-64 reduced the cleavage of this substrate by 2 80% indicating that the increase in activity is due principally to cysteine proteinases. PMA treatment in the presence of anti-uPA prevents cells from adhering and results in a significant reduction in cysteine proteinase activity (P = 0.012, n = 4). As indicated in Fig. 6 , the addition ofuPA (100 nM) at the time of addition of the antibody overcomes this effect, the cells adhere, and the induction of cysteine proteinase activity is restored.
PMA-stimulated and uPA antibody-treated cells express uPA receptors. To determine the status of uPA receptors on nonadhering HL60 cells stimulated by PMA in the presence of anti-uPA, analyses by flow cytometry were performed. The expression of uPA receptors as indicated by cell surface uPA staining is increased -30-fold on these nonadhering cells (Ta- Figure 6 . Anti-uPA (25 jul/ml) inhibits accumulation of cellular cysteine proteinase activity in response to PMA, and exogenous uPA overcomes this effect. Activity of total HL60 cell lysates, adherent and nonadherent, is shown. 100 nM uPA was used to reverse the effect of anti-uPA. Data represent E64 inhibitable cysteine proteinase activity.
ble I1). Adherence of mononuclear phagocytes is associated with cell surface expression ofmolecules from the integrin family (37, 38) . The effect of uPA antibodies on adhesion could be due to interference with the expression of these molecules. Therefore staining for CD 18, the invariant chain of a family of cell adhesion molecules, was also performed (25). The observed increase in CD 18 after the PMA pulse was about twofold (Table II) It is of interest that the growth factor domain augments the PMA-induced differentiation and adhesion of cells when added by itself (Fig. 5 ). This observation raises the possibility that in addition to an autocrine mechanism, uPA may influence myeloid cell differentiation in a paracrine fashion. Because fibroblasts, endothelial cells, neutrophils, and monocytes are able to secrete uPA (1), stromal and inflammatory cells may have a prominent role in modulating macrophage differentiation in vivo.
The secretion of plasminogen activators by human bone marrow cells has previously been linked to their differentiation. Early human granulocyte/macrophage progenitor cells secrete tissue-type plasminogen activator (tPA) whereas more mature granulocyte and macrophage progenitor cells secrete uPA (40, 41) . Although the reason for this change in pattern in enzyme secretion is not known, our data suggest a mechanism by which uPA secretion and myeloid cell differentiation may be mechanistically linked.
Evidence that the uPA receptor may transduce signalling has been suggested in other experimental systems. For certain epidermal cells, uPA has been found to be a weak mitogen, and the data have indicated that both the growth factor domain and the catalytic domain are necessary (42) . In view ofthese observations, we measured the proliferative response of HL60 cells after stimulation with exogenous uPA (0.8-100 nM range), and found that there was no change in 3H-thymidine uptake or induction ofadherence. Thus for these cells, uPA itselfdoes not induce differentiation and the second signal, PMA, which acts via protein kinase C is also required. Furthermore, it has been shown that uPA in the absence ofits catalytic activity can mediate a chemotactic role for neutrophils and aortic endothelial cells indicating that the uPA receptor can alter cell activity (43, 44) . Murine erythroleukemia (Friend) cells differentiated in vitro have a significant reduction in time for commitment to terminal differentiation when cultured in the presence of ATF (45) , consistent with our observations with the effect of the GFD-peptide and ATF on PMA-stimulated myeloid cells.
These and our observations contrast with those where the catalytic domain ofuPA bound to its receptor appears to play a role in matrix metabolism and detachment from culture surfaces. For Rous sarcoma virus-transformed chicken embryo fibroblasts and mesangial epithelial cells, treatment with antiuPA directed against the catalytic uPA domain promotes adhesion and prevents the morphological effects induced by PMA or cyclic-AMP mediated pathways (46, 47) . Moreover, in maturing Friend erythroleukemia cells, where evidence exists for a role ofATF in inducing differentiation, monoclonal antibodies directed against the catalytic domain promote adhesion on fibronectin coated surfaces presumably by interfering with metabolism of the matrix (48) .
Induction of cathepsin B-like lysosomal proteinase activity is a reliable marker of macrophage differentiation (32, 35, 36) . Our data show that the addition of uPA antibodies to PMAstimulated HL60 cells not only blocked induction of this proteinase activity, but also resulted in lower fluorometric activity than that ofunstimulated cells (Fig. 6) . The reason for the latter is not clear. It is possible that uPA has a "trophic" effect for these cells along the lines reported for various colony stimulating factors (49) . This would be consistent with the small decrease in viability in antibody-treated cells as compared with control unstimulated cells. It is also possible that the fluorometric activities in control and PMA-stimulated and uPA antibody-treated cells are due to different enzymes. The synthetic substrate employed could be hydrolyzed by more than one cysteine proteinase. Since our data show that not all attributes of PMA-induced differentiation are blocked by uPA antibodies (Table II) , the lower activity in PMA-stimulated and antibody treated cells compared to unstimulated cells could reflect a difference in enzyme ratio during a state ofstimulation when cells cannot adhere.
Accumulating evidence indicates that cell shape and cellular interactions with extracellular matrices modulate gene expression and differentiation (50) (51) (52) . For example, adhesion of monocytes to plastic surfaces has been reported to regulate cfos and m-CSF mRNA (53) . Adhesion appears to be both a marker for and an intrinsic part of myeloid cell differentiation. Our data indicate that uPA receptor binding modulates both cathepsin B-like enzyme expression as well as cell adhesiveness. It remains to be defined whether the observed block in cathepsin B-like activity (Fig. 6 ) results from attenuated adhesiveness or from a more proximate block in differentiation affecting both markers. A useful aspect of the experimental system presented here is that it offers a convenient model where the consequences of interaction of uPA with its receptor can be explored. Further structural and functional studies should delineate the importance of this pathway in understanding another set of mechanisms which regulate myeloid cell behavior.
